Navigation Links
Medivation Announces Third Quarter 2010 Financial Results Teleconference and Webcast on November 5, 2010
Date:10/29/2010

SAN FRANCISCO, Oct. 29 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that it will host a teleconference and webcast with management to discuss third quarter 2010 financial results and provide a general business update on November 5, 2010, at 4:30 p.m. Eastern Time. A press release for the third quarter ended September 30, 2010 will be released after markets close on November 5, 2010.

Interested parties may call 877-303-2523 from the U.S. or +1-253-237-1755 internationally. Individuals interested in listening to the live call via webcast may do so by visiting http://www.medivation.com. A replay of the webcast will be available on the Company's website for 30 days.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. Together with its corporate partners Pfizer and Astellas, Medivation currently has investigational drugs in Phase 3 development to treat advanced prostate cancer, mild-to-moderate Alzheimer's disease and Huntington disease. For more information, please visit us at www.medivation.com.


'/>"/>
SOURCE Medivation, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Medivation Announces Second Quarter 2010 Financial Results Teleconference and Webcast on August 9, 2010
2. Medivation Announces Organizational Changes to Support Anticipated Growth and Future Commercialization
3. Medivation Reports Third Quarter 2009 Financial Results and Provides Corporate Update
4. Astellas and Medivation Enter Into Worldwide Agreement to Co-Develop and Co-Commercialize MDV3100 for the Treatment of Prostate Cancer
5. Medivation Announces Initiation of Phase 3 Clinical Trial of MDV3100 in Advanced Prostate Cancer
6. Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients
7. Pfizer and Medivation Initiate Phase 3 Trial of Dimebon Added to Donepezil in Patients with Alzheimers Disease
8. Medivation Completes Enrollment of Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients
9. Medivation Presents Positive New Data on Dimebons Long-Term Efficacy and Novel Mechanism of Action at the International Conference on Alzheimers Disease
10. Medivation Announces Publication in The Lancet of Dimebon Pivotal Trial Results in Alzheimers Disease
11. Medivation Announces Positive Top-Line Results From Phase 2 Dimebon Study in Huntingtons Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/12/2017)... , June 12, 2017 Kineta, Inc., a biotechnology ... Kineta Vice President of R&D and Head of ... Pandemic Preparedness for the Northwest and Beyond meeting ... on June 14, 2017 from 8:30-10:30 AM PDT at the ... Dr. Bedard will be joined by other ...
(Date:6/9/2017)... and INDIANAPOLIS , June 9, ... living with diabetes. In a further effort to help ... affected by this condition, the International Diabetes Federation (IDF) ... ) have come together for the second phase of ... Systems programme (BRIDGES 2), reaffirming their commitment to helping ...
(Date:6/7/2017)... -- Endo International plc (NASDAQ: ENDP ) ... Joseph R. Goodwin , U.S. District Court Judge for ... , entered a case management order in MDL 2325, ... Litigation (the "MDL") that includes a provision requiring plaintiffs ... on specific causation within one hundred twenty (120) days ...
Breaking Medicine Technology:
(Date:6/22/2017)... ... 2017 , ... Vighter, a premier provider of Unconventional Medical ... PSC.1-2012. The company’s work in countries throughout Southwest Asia, South America, and the ... degraded. The PSC.1 standard was created to protect fundamental freedoms and human rights ...
(Date:6/20/2017)... (PRWEB) , ... June 20, 2017 , ... ... services, announced today that Claritas Capital, a Nashville-based private equity firm, has invested ... our expansion plans for some time, and Claritas Capital offers the smart money, ...
(Date:6/20/2017)... ... June 20, 2017 , ... After months of negotiations, FaceCradle USA is proud to ... on Wednesday, June 21. , “Introducing our product on QVC is something we all worked ... our travel pillow to more than 90 million homes in the United States,” said FaceCradle ...
(Date:6/20/2017)... , ... June 20, 2017 , ... Fresenius Vascular Care, ... minimally invasive techniques to treat and manage a wide range of vascular conditions, has ... initiative. With more than 65 centers represented by more than 40 local brands, a ...
(Date:6/20/2017)... ... June 20, 2017 , ... HOUSTON – Brazos Towers at Bayou Manor ... of new options for today’s modern senior. Brazos Towers at Bayou Manor has more ... love while offering them the services to support that lifestyle both now and in ...
Breaking Medicine News(10 mins):